{"id":105383,"date":"2026-07-19T22:30:41","date_gmt":"2026-07-19T22:30:41","guid":{"rendered":"https:\/\/www.europesays.com\/ch\/105383\/"},"modified":"2026-07-19T22:30:41","modified_gmt":"2026-07-19T22:30:41","slug":"ubs-strongly-resets-lilly-stock-target","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/ch\/105383\/","title":{"rendered":"UBS strongly resets Lilly stock target"},"content":{"rendered":"\n

Eli Lilly (LLY<\/a>) has seen a lot of bullish calls from Wall Street<\/a> in July.\u00a0 <\/p>\n

Guggenheim, Truist, Bank of America, Bernstein, and JPMorgan<\/a> all raised their price targets in the first half of the month.\u00a0 <\/p>\n

Then UBS<\/a>went higher than nearly all of them. <\/p>\n

UBS’s call is worth watching closely because it landed in the same week as prescription data that point in a bearish direction. <\/p>\n

For anyone holding Lilly stock into its August earnings report, the gap between those two things is worth looking at. <\/p>\n

UBS raises its Eli Lilly price target to $1,425 <\/p>\n

On July 13, UBS analyst Michael Yee<\/a> lifted his price target on Eli Lilly to $1,425 from $1,250 and kept a buy rating.\u00a0 <\/p>\n

That is a 14% increase from the previous target, and it implies a roughly 20% boost from where the stock traded on the July 13. <\/p>\n

More Health Care Stocks: <\/p>\n

Yee tied the raise to sales momentum in Mounjaro and Zepbound, Lilly’s diabetes and obesity injections. He also cited optimism around Kisunla, its Alzheimer’s treatment, Financial Modeling Prep<\/a> reported. <\/p>\n

A buy rating means the analyst expects the stock to outperform. The $1,425 figure is where he thinks shares could trade over the next 12 months. <\/p>\n

UBS was not alone. Guggenheim moved to $1,273, BofA to $1,334, Truist to $1,370, and Bernstein to $1,385, all in the same stretch, according to GuruFocus<\/a>. <\/p>\n

<\/a> UBS raised its Eli Lilly price target to $1,425, citing Mounjaro and Zepbound demand.JHVEPhoto &sol; Getty Images Why Mounjaro and Zepbound sales support the Lilly target <\/p>\n

The bull case rests on a business that has been growing at a pace that’s rare for major pharmaceutical companies. <\/p>\n

In the first quarter of 2026, revenue rose 56% to $19.8 billion, and Lilly raised full-year guidance to between $82 billion and $85 billion, Lilly<\/a>‘s earnings release showed. <\/p>\n

What the franchise delivered in Q1 <\/p>\n

Mounjaro brought in $8.66 billion worldwide, more than doubling from the same quarter in 2025. <\/p>\n

U.S. Zepbound sales reached $4.16 billion, up 80%. <\/p>\n

U.S. revenue climbed 43% to $12.1 billion on a 49% jump in volume. <\/p>\n

Adjusted earnings came to $8.55 per share against a $6.66 consensus, CNBC<\/a> reported. <\/p>\n

Volume did that work, not price. Realized prices fell in both markets, and demand still overwhelmed the drag. <\/p>\n

That is the pattern Lilly’s management promised, and it is the reason analysts keep moving their targets up. <\/p>\n

The Foundayo prescription data complicating the bullish view <\/p>\n

Foundayo, Lilly’s oral GLP-1 pill, launched in April and was supposed to widen the market to patients who will not take an injection.\u00a0 <\/p>\n

Story Continues <\/p>\n

However, weekly prescriptions have been flat for five weeks, Fierce Pharma<\/a> reported, citing IQVIA data in a July 10 Jefferies note. <\/p>\n

Foundayo versus the Wegovy pill at week 13 <\/p>\n

Foundayo: 19,550 weekly prescriptions, down for a third straight week from a week-10 peak of 21,648. <\/p>\n

Novo Nordisk Wegovy pill: More than 105,000 at the same point after launch. <\/p>\n

Jefferies projects $71 million in debut-quarter Foundayo sales, against a Wall Street consensus near $130 million. <\/p>\n

There are fair explanations for the performance. Oral Wegovy is semaglutide, a molecule doctors already knew, while Foundayo is a new compound with a new brand name. <\/p>\n

Coverage also arrived late, as CVS<\/a> was the last of the three big pharmacy benefit managers to cover Foundayo, while Wegovy had full coverage in its first week.\u00a0 <\/p>\n

Employer appetite<\/a> for GLP-1 coverage is also a separate pressure on the same demand curve. <\/p>\n

What the Kisunla and Alzheimer’s angle actually adds <\/p>\n

The second leg of the UBS thesis is Kisunla, and the timing is planned.\u00a0 <\/p>\n

Lilly<\/a> presented 16 abstracts at the Alzheimer’s Association International Conference in London from July 12 to 15. <\/p>\n

Related: Eli Lilly’s hottest drugs face a quiet new threat<\/a> <\/p>\n

The headline items were long-term extension data on Kisunla’s benefit-risk profile and a comparison of P-tau217 blood tests against amyloid PET scans in patients with no symptoms yet. <\/p>\n

That second item matters a lot.\u00a0 <\/p>\n

PET scans are expensive and scarce, so a blood test that finds Alzheimer’s early would widen the pool of diagnosed patients, and every diagnosed patient is a potential Kisunla candidate. <\/p>\n

However, it is years from moving the revenue line the way Mounjaro does today. <\/p>\n

How Lilly stock has traded against its own good news <\/p>\n

The stock has not been keeping pace with analysts’ optimism. <\/p>\n

LLY share-price snapshot: <\/p>\n

Closed at $1,152.54 on July 14, down 4.89% over five trading days. <\/p>\n

Up 11.58% over the past six months, and still up on the year. <\/p>\n

52-week range of $623.78 to $1,249.45, with the all-time closing high of $1,235.56 set July 7. <\/p>\n

Market value near $1.09 trillion, with a price-to-earnings ratio<\/a>around 41. <\/p>\n

The stock set a record on July 7, then gave back nearly 5% into the week UBS raised its target.\u00a0 <\/p>\n

At $1,152.54, the $1,425 target implies about 24% upside, wider than the roughly 20% measured on the day of the call. <\/p>\n

A price-to-earnings ratio in the low 40s means investors are already paying for years of growth that has not arrived yet, which is exactly why a lagging sales number can move the shares. <\/p>\n

What Eli Lilly investors should watch before Aug. 5 <\/p>\n

Lilly reports second-quarter results on Aug. 5, and the report is a straightforward test for the stock. <\/p>\n

Three things that decide whether $1,425 holds: <\/p>\n

Foundayo’s reported quarterly sales: Consensus sits near $130 million, and Jefferies models $71 million, so the actual figure settles whether the IQVIA data was missing telehealth scripts or telling the truth. <\/p>\n

Mounjaro’s international momentum: Growth outside the U.S. ran 81% last quarter, helped by China adding Mounjaro to its reimbursement list, and generics are coming to some markets. <\/p>\n

Whether volume keeps outrunning prices: Realized prices are falling in both the U.S. and abroad, and the whole thesis depends on demand growing faster than that decline. <\/p>\n

Mounjaro and Zepbound are performing, and nobody disputes that. <\/p>\n

For long-term investors, the August report tells you whether Foundayo is simply experiencing a slow start or whether the drug is a miss. <\/p>\n

If you’re looking at adding LLY to your portfolio, keep in mind that six banks raised their targets into the same crowded trade this month, and the stock is already 8% off its high with a $1,425 target.\u00a0 <\/p>\n

At this multiple, one bad quarter is enough to hurtthe stock, so size your position accordingly. <\/p>\n

Related: Goldman Sachs doubles down on Novo stock target after key event<\/a> <\/p>\n

This story was originally published by TheStreet<\/a> on Jul 16, 2026, where it first appeared in the Investing<\/a> section. Add TheStreet as a Preferred Source by clicking here.<\/a> <\/p>\n","protected":false},"excerpt":{"rendered":"Eli Lilly (LLY) has seen a lot of bullish calls from Wall Street in July.\u00a0 Guggenheim, Truist, Bank…\n","protected":false},"author":2,"featured_media":105384,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[129],"tags":[216,30285,42747,51678,5255,223],"class_list":["post-105383","post","type-post","status-publish","format-standard","has-post-thumbnail","category-ubs","tag-eli-lilly","tag-michael-yee","tag-mounjaro","tag-prescription-data","tag-target","tag-ubs"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@ch\/116949013379516526","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/105383","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/comments?post=105383"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/105383\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media\/105384"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media?parent=105383"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/categories?post=105383"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/tags?post=105383"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}